EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A butyrate‐producing synbiotic mitigates intestinal inflammation in a murine colitis model

Hyuna Sung, Soo Yoon Cho, Seong Hyeok Ma, Jin Sun You, Mi Young Yoon, Sang Sun Yoon iD

mLife · 2025-08 · 4 (4) · 397-408

DOI: 10.1002/mlf2.70027 ↗

Kurz gefasst

Fachartikel in der Zeitschrift mLife, online erschienen am 30.07.2025. Verfasst von Hyuna Sung und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology Yonsei University College of Medicine Seoul Republic of Korea. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inflammatory bowel disease (IBD) is a chronic condition characterized by intestinal inflammation and gut dysbiosis, with limited treatment options primarily focused on immune‐modulating therapies. Among potential therapeutic agents, butyrate has emerged as a promising candidate due to its anti‐inflammatory and gut‐restorative properties. However, direct administration of butyrate poses significant challenges, including its rapid absorption, uneven distribution within the intestinal tract, and an unpleasant odor that reduces patient compliance. To address these issues, we evaluated the therapeutic potential of Bacillus subtilis BM107, a strain selected for its superior butyrate‐producing capabilities and established bacterial safety. BM107 efficiently hydrolyzed tributyrin (TB), a butyrate prodrug, producing substantial butyrate levels in TB‐supplemented media. In a dextran sodium sulfate‐induced colitis mouse model, co‐administration of BM107 and the TB diet significantly improved inflammatory indices, such as reduced disease activity index scores, increased colon length, and restored body weight. Additionally, this combination treatment markedly improved gut microbiome composition, restoring microbial diversity and balance. Furthermore, butyrate levels in the cecum contents of the TB + BM107 group were restored to levels comparable to those in healthy controls, demonstrating the ability of this approach to promote gut homeostasis and intestinal recovery. These findings highlight the therapeutic potential of BM107 combined with a TB diet as a safe, effective, and innovative strategy for addressing gut dysbiosis and inflammation in IBD, paving the way for the development of microbiome‐based bacterial therapeutics to improve patient outcomes.

Schlagwörter

Stichwörter der Autor:innen

Bacillus subtilisIBDbutyrateesterasetributyrin

Autor:innen und Institutionen

  • Department of Microbiology and Immunology Yonsei University College of Medicine Seoul Republic of Korea.
  • Institute for Immunology and Immunological Diseases Yonsei University College of Medicine Seoul Republic of Korea.
  • BioMe Inc. Seoul Republic of Korea.

ORCID-Profile: Sang Sun Yoon

Zitieren

APA

Sung, H., Cho, S. Y., Ma, S. H., You, J. S., Yoon, M. Y., & Yoon, S. S. (2025). A butyrate‐producing synbiotic mitigates intestinal inflammation in a murine colitis model. mLife, 4(4), 397-408. https://doi.org/10.1002/mlf2.70027

Vancouver

Sung H, Cho SY, Ma SH, You JS, Yoon MY, Yoon SS. A butyrate‐producing synbiotic mitigates intestinal inflammation in a murine colitis model. mLife. 2025;4(4):397-408. doi:10.1002/mlf2.70027

BibTeX
@article{Sung2025,
  author = {Sung, Hyuna and Cho, Soo Yoon and Ma, Seong Hyeok and You, Jin Sun and Yoon, Mi Young and Yoon, Sang Sun},
  title = {A butyrate‐producing synbiotic mitigates intestinal inflammation in a murine colitis model},
  journal = {mLife},
  year = {2025},
  volume = {4},
  number = {4},
  pages = {397--408},
  doi = {10.1002/mlf2.70027}
}
Kostenlos starten →